Reporting on the Safety of Dementia Care for 2010-2021 in South Korea

Author:

Lee Jong hoon1

Affiliation:

1. Seoul National University College of Medicine

Abstract

Abstract

This is the second report on the benefit or risk of treatment with anti-Alzheimer’s disease (AD) drugs (AADs). As a tool for monitoring citizen health, we use information from the National Health Service (NHIS) for all citizens via an information retrieval engine to link International Classification of Diseases (ICD)-10 codes and death tables of AADs with big data to create a standard comparison between AADs and deaths over 12 years. According to the International Classification of Disease-10 (ICD-10) codes, the correlation between the trend in the number of deaths and the number of deaths per 100,000 people was analyzed via the National Health Insurance System (NHIS) through the decision of the Open Data Mediation Committee of South Korea (case number: 2020-029) and information disclosure (20240110). The Dementia Management Act (DMA) in South Korea was enacted in 2012 and all dementia subjects are registered at Central Dementia Center. In completely blinded randomized states, we enrolled subjects from 2012 (the year of the Dementia Management Act) to 2018 (the year of the Dementia National Responsibility System was implemented). We observed a correlation between the AD and AAD groups from 2005 to 2019 on Sorok Island and from 2010 to 2021 on the NHIS of South Korea. This study investigated the increase and decrease in mortality in AD patients with AAD. We analyzed the mortality per 100,000 people with the R2. A simple linear equation was applied to trace the increase (+) or decrease (-) in deaths with the Friedman and Kolmogorov‒Smirnov tests for decisions on the listed, delisted, and sustainable drugs based on R2 > 0.75. Total deaths from AD caused by AAD decreased (R2, 0.993) from 2010 to 2021. From 2012 to 2018, the drugs listed to reduce deaths were fluoxetine (R2, 0.826), escitalopram (0.955) and galantamine (0.825) in South Korea. The delisted drugs used were donepezil (0.861), rivastigmine (0.754), risperidone (0.816), quetiapine (0.977), and haloperidol (0.973). The sustainable drugs used were memantine (0.108), olanzapine (0.124), fluvoxamine (0.001), oxcarbazepine (0.52), and trazodone (0.331). With the 12-year trend, galantamine, fluoxetine, could be therapeutics for AD, and sertraline and aripiprazole could be therapeutics; however, additional observation is needed. Deaths and AADs based on NHIS big data could be useful for safe dementia care.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3